AGC Pharma Chemicals has been officially accredited as a private research organization under France’s Crédit d’Impôt Recherche (CIR) framework for 2025–2027, granted by the French Ministry of Higher Education, Research and Space, reinforcing its position as an R&D and manufacturing partner for pharmaceutical and biotech companies in France.
For French pharmaceutical and biotech companies, the accreditation also brings a potential financial advantage. Companies outsourcing qualifying R&D activities to AGC Pharma Chemicals may be able to include those expenses in their CIR calculation, subject to the eligibility requirements established under French legislation. The CIR tax benefit is generally equivalent to 30% of eligible R&D expenses, up to €100 million in annual R&D expenditure.
Supporting small-molecule R&D from development to manufacturing
The accreditation complements AGC Pharma Chemicals’ capabilities as an integrated CDMO for small molecules. The company supports pharmaceutical programs across process development and optimization, analytical development, scale-up, and API and HPAPI manufacturing, helping customers build robust and scalable processes as their molecules progress through development.
For pharmaceutical and biotech companies in France, CIR accreditation adds another dimension to working with AGC Pharma Chemicals: access to specialized small-molecule development expertise through an officially accredited R&D organization, together with the potential to incorporate eligible outsourced R&D expenditure into their CIR claims.
